Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.50M | $15.5M | $8.33M | $9.77M |
| Revenue growth | — | — | — | — | 517.5% | -46.1% | 17.3% |
| Operating income | — | -$43.0M | -$173M | -$162M | -$72.4M | -$91.5M | -$110M |
| Operating margin | — | — | — | -6492.7% | -468.8% | -1097.6% | -1130.6% |
| Net income | — | -$60.0M | -$175M | -$166M | -$112M | -$89.3M | -$109M |
| Net margin | — | — | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (diluted) | — | -$3.40 | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$30.7M | -$117M | -$88.4M | -$73.0M | -$81.2M | -$93.1M |
| Capital expenditures | — | $82.0K | $15.3M | $20.6M | $3.87M | $374K | $738K |
| Free cash flow | — | -$30.8M | -$132M | -$109M | -$76.9M | -$81.6M | -$93.8M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $251M | $149M | $87.9M | $144M | $139M | $320M |
| Total assets | $15.0K | $259M | $214M | $126M | $173M | $160M | $343M |
| Total liabilities | $150K | $7.58M | $119M | $125M | $97.8M | $88.8M | $96.4M |
| Long-term debt | — | — | $37.2M | $38.0M | $40.5M | $43.9M | $50.1M |
| Shareholders' equity | -$135K | $251M | $95.4M | $949K | $74.9M | $71.5M | $247M |
| Retained earnings | -$1.11M | -$61.1M | -$236M | -$401M | -$513M | -$602M | -$711M |
| Shares (wtd avg diluted) | 10.9M | 37.8M | 37.7M | 44.0M | 116M | 250M | 320M |
Every figure is extracted from Taysha Gene Therapies, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.